Abstract:The live-attenuated oral polio vaccine (OPV) will be no longer used when wild poliovirus (WPV) eliminating in worldwide, according to GPEI (the Global Polio Eradication Initiative) Reports. It is planning to replace OPV by Sabin-based inactivated poliovirus vaccine (sIPV) in developing countries, with purpose of reducing of the economic burden and maintaining of the appropriate antibody levels in population. It studied serial fractional doses immunized by intradermal injection (ID) in rats, to reduce consume o… Show more
“…Induction of sufficient immune responses by ID delivery of the fractional dose of an existing formulation was encouraging. Since reformulation of existing vaccine needs expensive processes, the present results may facilitate the development of ID delivery as an alternative to SC/IM vaccination.…”
The microneedle unit presented here delivered solution intradermally without any difficulty and evoked antibody responses against viruses even with the reduced vaccine volume. Our findings confirm promising results of ID delivery as an immunogenic option to enhance vaccination efficacy.
“…Induction of sufficient immune responses by ID delivery of the fractional dose of an existing formulation was encouraging. Since reformulation of existing vaccine needs expensive processes, the present results may facilitate the development of ID delivery as an alternative to SC/IM vaccination.…”
The microneedle unit presented here delivered solution intradermally without any difficulty and evoked antibody responses against viruses even with the reduced vaccine volume. Our findings confirm promising results of ID delivery as an immunogenic option to enhance vaccination efficacy.
“…According to the WHO, the ID route of delivery could reduce the required antigen by 1/5 of the full vaccine . In our previous study, we found that a 1/5 fractional dose could be used by ID injection to prevent poliovirus infection. However, ID delivery might not be suitable for KML05.…”
Section: Discussionmentioning
confidence: 99%
“…Antibody determination was done by the standard microneutralization technique using Vero cells. The definition of seroconversion rate was consistent with our previous study . Quality‐control requirements were as follows: the serum was heated for half an hour at 56℃ and tested in six steps by twofold dilutions, with a final dilution of 1:320.…”
Our research team developed KML05 adjuvant, which combined carbopol971P with MF59, increased antibody responses to sIPV for a longer duration of protection in a rat model.
“…ID delivery has been proposed as a means to reduce the dose required for vaccination, and it has been shown in several phase 3 trials in infants and adults to be a promising option to dose-spare by 60–80%, despite certain limitations(e.g., dose regimen and age). 10-13 For sIPV, our laboratory conducted pioneering ID tests in rats 14 and found out that the dose could be reduced by 80%, thus, further clinical trials are in preparation. In parallel with ID tests for sIPV, we also seek to determine optimal adjuvants for sIPV.…”
Sabin-based inactivated poliovirus vaccine(sIPV) is gradually replacing live-attenuated oral polio vaccine(OPV). Sabin-inactivated poliovirus vaccine(sIPV) has played a vital role in reducing economic burden of poliomyelitis and maintaining appropriate antibody levels in the population. However, due to its high cost and limited manufacturing capacity, sIPV cannot reach its full potential for global poliovirus eradication in developing countries. Therefore, to address this situation, we designed this study to evaluate the dose-sparing effects of AS03, CpG oligodeoxynucleotides (CpG-ODN) and polyinosinic:polycytidylic acid (PolyI:C) admixed with sIPV in rats. Our results showed that a combination of 1/4-dose sIPV adjuvanted with AS03 or AS03 with BW006 provides a seroconversion rate similar to that of full-dose sIPV without adjuvant and that, this rate is 5-fold higher than that of 1/4-dose sIPV without adjuvant after the first immunization. The combination of AS03 or AS03 with BW006 as an adjuvant effectively reduced sIPV dose by at least 4-fold and induced both humoral and cellular immune responses. Therefore, our study revealed that the combination of AS03 or AS03 with BW006 is a promising adjuvant for sIPV development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.